European Commission approves AbbVie's MAVIRET for acute Hepatitis C treatment
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Subscribe To Our Newsletter & Stay Updated